Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy

Impact · against what's priced in

Akari Therapeutics provides proof-of-concept data showing AKTX-101 can overcome resistance to first-generation TROP2 ADCs in urothelial cancer. While the mid-2027 Phase 1 timeline is distant, the data validates their novel RNA spliceosome-modulating payload strategy.

AKTX+0.60

No priced-in read yet